Mekaniska modellering av nanopartikel-formuleringar
Research Project, 2022 – 2023

Nanosized particles containing drug molecules can be administered intravenously to increase the drug load of injectable formulations when the drug solubility is limiting, or to alter the distribution and drug release to avoid toxicity or improve the duration of pharmacological actions. As such, these novel complex formulations are mainly used in the field of oncology. To facilitate the design and development of such nanoparticle formulations, physiologically based biopharmaceutics models (PBBM) could be used to simulate the drug performance in vivo. While such models have been used for other formulations, a PBBM including nanoparticle transport would be a novel development. Furthermore, basing the model on first principles would enable validation of parts of the model in vitro and make the model translatable between species. This project proposal suggests funding for senior researcher Tobias Gebäck, Mathematical sciences, Chalmers, to spend two years at 50% at AstraZeneca developing and implementing such models. The project would have a major impact on the development of novel nanosized formulations, in particular for tumor treatment. It would reduce the extent of animal testing required and enable exploratory research of innovative solutions that cannot be studied in vivo. The main deliverable is a PBBM of the body, including mechanistic models of nanoparticle transport, drug release from nanoparticles and a solid tumor model, together with suitable numerical tools.


Tobias Gebäck (contact)

Chalmers, Mathematical Sciences, Applied Mathematics and Statistics


AstraZeneca AB

Södertälje, Sweden

University of Gothenburg

Gothenburg, Sweden


Swedish Foundation for Strategic Research (SSF)

Project ID: SM21-0057
Funding Chalmers participation during 2022–2023

More information

Latest update